Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - tirotropin alfa - Širokopasemske neoplazme - spodnjega režnja hipofize hormoni in analogi, hipofize in hypothalamic hormoni in analogi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi je označen kot monotherapy pri odraslih za zdravljenje polycythaemia vera brez simptomatsko splenomegaly.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, kronični - antivirusi za sistemsko uporabo - incivo, v kombinaciji z peginterferon alfa in ribavirin, je primerna za zdravljenje genotip-1 kronični hepatitis c pri odraslih bolnikih z odškodnina za bolezni jeter (vključno s cirozo):kdo so zdravljenje naivna;, ki so že bili zdravljeni z interferonom alfa (pegylated ali ne-pegylated) sam ali v kombinaciji z ribavirin, vključno z relapsers, delno odzvali in nič na kraju nesreče.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 50 µg / 1 tableta - natrijev levotiroksinat

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 200 mg / 1 tableta - natrijev levotiroksinat

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 100 mg / 1 tableta - natrijev levotiroksinat

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 25 mg / 1 tableta - natrijev levotiroksinat

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 150 mg / 1 tableta - natrijev levotiroksinat

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - natrijev levotiroksinat - tableta - natrijev levotiroksinat 50 µg / 1 tableta - natrijev levotiroksinat

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.